Compare · AZN vs CPRX
AZN vs CPRX
Side-by-side comparison of AstraZeneca PLC (AZN) and Catalyst Pharmaceuticals Inc. (CPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and CPRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 68.2x CPRX ($3.85B).
- AZN has hit the wire 15 times in the past 4 weeks while CPRX has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 7 for CPRX).
- Company
- AstraZeneca PLC
- Catalyst Pharmaceuticals Inc.
- Price
- $167.29-1.40%
- $31.49+0.03%
- Market cap
- $263.10B
- $3.85B
- 1M return
- -
- +0.41%
- 1Y return
- -
- +58.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2006
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 7
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Latest AZN
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Latest CPRX
- SEC Form 15-12G filed by Catalyst Pharmaceuticals Inc.
- Chief HR Officer Russo Gregg returned $14,994 worth of shares to the company (476 units at $31.50), closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Legal Officer Elsbernd Brian returned $7,638,782 worth of shares to the company (242,501 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- SEC Form 4 filed by Director Curran Daniel J. to cover taxes
- Director Thompson Tamar returned $118,850 worth of shares to the company (3,773 units at $31.50), closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Chief Op. & Scientific Officer Miller Steve returned $34,454,794 worth of shares to the company (1,093,803 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Director Tierney David S returned $12,074,391 worth of shares to the company (383,314 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax liability)
- Chief Strategy Officer Sundaram Preethi returned $1,726,326 worth of shares to the company (54,804 units at $31.50), closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Chairman of Board of Directors Mcenany Patrick J returned $131,404,108 worth of shares to the company (4,171,559 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- President and CEO Daly Richard J returned $8,544,879 worth of shares to the company (271,266 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for withholding tax)